Tactile Systems Technology, Inc. Revises Earnings Guidance for the Full Year 2023
August 07, 2023 at 04:05 pm
Share
Tactile Systems Technology, Inc. revised earnings guidance for the full year 2023. For the year, the company expects total revenue in the range of $274 million to $278 million, representing growth of approximately 11% to 13% year-over-year. The Company's prior 2023 revenue guidance expectations called for total revenue in the range of $271 million to $275 million, representing growth of approximately 10% to 11.5% year-over-year.
Tactile Systems Technology, Inc., doing business as Tactile Medical, is a medical technology company providing therapies for people with chronic disorders. The Company's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. It is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. It markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. The Company markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. The Company's Entre system is a basic pneumatic compression device. Kylee, its free mobile application, helps patients learn about lymphedema.